<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: 15-20% of <z:hpo ids='HP_0000001'>all</z:hpo> patients initially diagnosed with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> develop <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> and surgical resection remains the only potentially curative treatment available </plain></SENT>
<SENT sid="1" pm="."><plain>Current 5-year survival following R0-resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> is 28-39%, but recurrence eventually occurs in up to 70% </plain></SENT>
<SENT sid="2" pm="."><plain>To date, adjuvant chemotherapy has not improved clinical outcomes significantly </plain></SENT>
<SENT sid="3" pm="."><plain>The primary objective of the ongoing LICC trial (L-BLP25 In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e>) is to determine whether L-BLP25, an active <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy, extends recurrence-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) time over placebo in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients following R0/R1 resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>L-BLP25 targets MUC1 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, which is highly expressed in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS/DESIGN: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with stage IV colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> limited to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> are included </plain></SENT>
<SENT sid="8" pm="."><plain>Following curative-intent complete resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and of <z:hpo ids='HP_0000001'>all</z:hpo> synchronous/metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo </plain></SENT>
<SENT sid="9" pm="."><plain>Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c </plain></SENT>
<SENT sid="10" pm="."><plain>L-BLP25 930 μg once weekly for 8 weeks, followed by s.c </plain></SENT>
<SENT sid="11" pm="."><plain>L-BLP25 930 μg maintenance doses at 6-week (years 1&amp;2) and 12-week (year 3) intervals unless recurrence occurs </plain></SENT>
<SENT sid="12" pm="."><plain>In the control arm, CP is replaced by saline solution and L-BLP25 by placebo </plain></SENT>
<SENT sid="13" pm="."><plain>Primary endpoint is the comparison of recurrence-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) time between groups </plain></SENT>
<SENT sid="14" pm="."><plain>Secondary endpoints are overall survival (OS) time, safety, tolerability, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>/OS in MUC-1 positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Exploratory immune response analyses are planned </plain></SENT>
<SENT sid="16" pm="."><plain>The primary endpoint will be assessed in Q3 2016 </plain></SENT>
<SENT sid="17" pm="."><plain>Follow-up will end Q3 2017 </plain></SENT>
<SENT sid="18" pm="."><plain>Interim analyses are not planned </plain></SENT>
<SENT sid="19" pm="."><plain>DISCUSSION: The design and implementation of such a vaccination study in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is feasible </plain></SENT>
<SENT sid="20" pm="."><plain>The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion </plain></SENT>
<SENT sid="21" pm="."><plain>TRIAL REGISTRATION: EudraCT Number 2011-000218-20 </plain></SENT>
</text></document>